Αποτελέσματα Αναζήτησης
The NCCN Templates include chemotherapy, immunotherapy, supportive care recommendations, monitoring parameters, and safety instructions. Special instructions for self-administered chemotherapeutic agents are also provided. NCCN Templates enhance patient safety by allowing you to: • Standardize patient care • Reduce medication errors
NCCN Templates include: Chemotherapy. Immunotherapy. Targeted therapy. Supportive care recommendations. Monitoring parameters. Safety instructions. Special instructions for self-administered chemotherapeutic agents. NCCN Templates enhance patient safety by allowing you to: Standardize patient care. Reduce medication errors.
7 Δεκ 2022 · The following material represents a subset of chemotherapy and immunotherapy regimens that are used for the treatment of patients with breast cancer, both in the adjuvant and neoadjuvant settings.
1 Μαΐ 2018 · Dose-Dense AC + TH is often given with the goal of cure and administered either before surgery (neoadjuvant therapy) to shrink the size of the tumor, or after surgery (adjuvant therapy) to kill any cancer cells that may be still present in the body.
The NCCN has launched a complete library of NCCN Chemotherapy Order Templates (NCCN Templates) for the top 13 most frequently occurring tumor types. The NCCN Templates now include more than 600 peer-reviewed and evidence-based chemotherapy regimens for clinicians. New to the library are NCCN Templates for esophageal, gastric,
14 Δεκ 2023 · Women with early-stage breast cancer that meet criteria for HER2 positivity are treated with chemotherapy and trastuzumab as adjuvant treatment. This topic review will cover the use of adjuvant HER2-directed therapy plus chemotherapy in patients with HER2-positive, early-stage breast cancer (stage I to III).
Treatment overview. This treatment regimen consists of two parts: 4 cycles of AC, followed by 4 cycles of TH and 13 cycles of trastuzumab. Breast neoadjuvant/adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) three weekly. Breast adjuvant TH (DOCEtaxel and trastuzumab) three weekly.
